Difference between revisions of "Norsworthy Kelly J., et al. Clinical Cancer Research (2019) cited as Ref 601 in DOI: 10.1038/s41392-020-0110-5 (Q9864)"
Jump to navigation
Jump to search
(Created claim: Page(s) (P105): 6021-6025, #quickstatements; #temporary_batch_1590074839150) |
(Created claim: Fourth Author string (P152): Zhuang Luning, #quickstatements; #temporary_batch_1590155310798) |
||
| Property / Fourth Author string | |||
| + | Zhuang Luning | ||
| Property / Fourth Author string: Zhuang Luning / rank | |||
| + | Normal rank | ||
Revision as of 13:50, 22 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Norsworthy Kelly J., et al. Clinical Cancer Research (2019) cited as Ref 601 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Norsworthy Kelly J.
0 references
By Kunthel
0 references
Subramaniam Sriram
0 references
20
0 references
2019
0 references
Clinical Cancer Research
0 references
25
0 references
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia (English)
0 references
6021-6025
0 references
Zhuang Luning
0 references
